Skip to main navigation
Skip to search
Skip to main content
Sort by
Keyphrases
Transarterial Chemoembolization
100%
Hepatocellular Carcinoma
100%
Pembrolizumab
100%
Phase Ib Study
100%
95% Confidence Interval
30%
Progression-free Survival
20%
Synergistic Toxicity
20%
Tumor
10%
Mechanism of Action
10%
Liver
10%
Disease Progression
10%
Cirrhosis
10%
Dynamic Change
10%
Adaptive Immunity
10%
Median Overall Survival
10%
Duration of Response
10%
Tumor Size
10%
Diarrhea
10%
Combined Modality Therapy
10%
Clinical Development
10%
Dose-limiting Toxicity
10%
Objective Response Rate
10%
Circulating Tumor DNA (ctDNA)
10%
T Cell Subsets
10%
Stool
10%
Non-viral
10%
Peripheral T Cells
10%
Child-Pugh Class
10%
Bacterial Profile
10%
Skin Rash
10%
Immunotherapy Efficacy
10%
Median Progression-free Survival
10%
Determinants of Response
10%
Treatment-related Adverse Events
10%
Serum Metabolites
10%
Host Determinants
10%
Medicine and Dentistry
Hepatocellular Carcinoma
100%
Transcatheter Arterial Chemoembolization
100%
Pembrolizumab
100%
Progression Free Survival
30%
Neoplasm
20%
Immunotherapy
20%
Disease Exacerbation
10%
Survival Rate
10%
Overall Survival
10%
Adaptive Immunity
10%
Diarrhea
10%
Liver Cirrhosis
10%
T Cell Subset
10%
Exanthem
10%
Circulating Tumor DNA
10%
Child-Pugh Score
10%
Serum Metabolite
10%
Median Follow Up
10%
Adverse Event
10%
Pharmacology, Toxicology and Pharmaceutical Science
Liver Cell Carcinoma
100%
Pembrolizumab
100%
Progression Free Survival
42%
Neoplasm
28%
Immunotherapy
28%
Survival Rate
14%
Disease Exacerbation
14%
Liver Cirrhosis
14%
Overall Survival
14%
Adverse Event
14%
Diarrhea
14%
Rash
14%
Circulating Tumor DNA
14%